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Abstract: The natural history of severe hemoglobinopathies like sickle cell disease (SCD) is 
rather variable, depending on the circumstances, but the main influence on such variability is 
the level of fetal hemoglobin (HbF) in the patient’s red cells. It is well known that a significant 
HbF level is associated with a milder course of disease and fewer complications. Therefore, 
attempts have been made to reactivate using various means the HbF production, which is nor-
mally switched off perinatally. A pharmacological approach has been attempted since the 1980s, 
ranging from drugs like 5-azacytidine and its derivative, decitabine, to a series of compounds 
like hydroxyurea and a number of histone deacetylase inhibitors like butyrate, which seem to 
act as epigenetic modifiers. Many other disparate agents have been tried with mixed results, but 
hydroxyurea remains the most effective compound so far available. Combinations of different 
compounds have also been tried with some success. Established treatments like bone marrow 
or cord blood transplantation are so far the only real cure for a limited number of patients with 
severe hemoglobinopathies. Improved chemotherapy regimens of milder toxicity than those 
employed in the past have made it possible recently to obtain a stable, mixed donor-recipient 
chimerism, with reversal of the SCD phenotype. However, great effort is directed to cell 
  engineering, searching for an effective gene vector by which a desired gene can be transferred 
into new classes of vectors for autologous hemopoietic stem cells. Recent studies are also aiming 
at targeted insertion of the therapeutic gene into hemopoietic cells, which can also be “induced” 
human stem cells, obtained from somatic dedifferentiated cells. Attention in this area must be 
paid to the possibility of undesired effects, like the emergence of potentially oncogenic cell 
populations. Finally, an update is presented on improved HbF determination methods, because 
common international standards are becoming mandatory.
Keywords: sickle cell disease, hemoglobin F, determinants, inducers, cell engineering, induced 
pluripotent stem cells
Introduction
In the wide spectrum of congenital hemoglobin disorders, two entities have always 
attracted attention because of their severity and extensive geographic distribution, 
ie, beta thalassemia major and sickle cell disease (SCD). In the present review,   attention 
is focused on the latter disease, characterized by a qualitative defect in   beta-globin 
  production, due to replacement of a single amino acid (valine for   glutamic acid) in the 
beta-globin chain and formation of an anomalous hemoglobin, called   hemoglobin S. This 
induces severe deformity of red cells upon deoxygenation,   hampering   microcirculation, 
and leading to vascular occlusion and critical organ damage.1
However, it has been noted that the natural history of this disease shows considerable 
heterogeneity in signs and symptoms, due to a variety of concomitant situations. Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Actually, the main factor in the variable severity of SCD is 
the level of fetal hemoglobin (HbF) produced by patients. 
There are indeed many disparate conditions, in which a higher 
level of HbF than expected can be found. They range from 
hereditary disorders to acquired ones, as well as from blood 
diseases to nonhematological situations (Table 1). It is well 
known that populations showing a genetically determined 
presence of HbF have a milder form of SCD, including 
a reduced incidence of severe clinical complications.2 It is 
therefore understandable that many efforts have been directed 
to restore the production of HbF in adults.3
As for the background of this process, recent studies 
have produced a good amount of information, particularly on 
gamma-globin gene control. In the present paper, we therefore 
propose a brief initial survey of these genetic factors, and then 
focus on new ways of drug treatment for reactivation of HbF 
level, as well as attempts at correction of the genetic defect by 
cell engineering. A brief update on recent methods for HbF 
assay is also included.
Genetics of HbF
It is well known that only a tiny fraction of HbF is still present 
in the majority of adults, as a result of the switch to HbA in 
early life. However, the switch may be impaired by a number 
of mutations in the beta-globin cluster,4 leading to uniform 
increase of HbF (pancellular hereditary persistence of fetal 
hemoglobin [HPFH]), a condition allowing a normal way of 
life, or to a nonuniform distribution of HbF, based on the coex-
istence of two populations of red cells, one with a high content 
of HbF (so-called F cells) and another with a negligible amount 
of the same. In this case, the condition is called heterocellular 
HPFH, which is regarded as a multifactorial quantitative trait, 
quite distinct from the classical form of pancellular hereditary 
persistence of fetal hemoglobin.5
A number of interesting studies have proposed different 
mechanisms which may be responsible for such persistence 
of HbF in adults, and can be either mutations in critical 
genic regions involved in the activation of globin genes or 
deletions of the globin gene cluster. Examples of the former 
event are single base substitutions in the promoter region 
of the gamma-globin genes, found in adults with high HbF 
production,6 or T to C substitution in the gamma-globin 
gene, leading to disruption of the assembly of a repressive 
chromatin structure, which normally silences the expression 
of the gamma-globin gene in adult erythrocytes.7 In the latter 
case, (ie, deletional persistence of HbF), Gazouli et al,8 
attempting to explain the production of the HbF phenotype 
in adult red cells, carried out an investigation in transgenic 
mice   lacking two elements of the Aγ-to-δ gene region, sug-
gesting that a deletion of silencer elements in that gene region 
may account for persistent expression of HbF in the adult 
stage. Previous experiments by the same authors had shown 
that a juxtaposition of downstream enhancers may also con-
tribute to that effect, but different models are not   mutually 
exclusive. According to another study, a downregulation 
of the   transcriptional repressor, ZHX2, or some chromatin 
remodelling factors may also be involved in deletional 
  hereditary persistence of fetal hemoglobin.9 Anyway, there is 
an obvious benefit from the analysis of multiple mechanisms 
of HbF persistence in adults, namely a better understanding 
of the molecular basis for the perinatal hemoglobin switch.
As far as possible genetic determinants of HbF production 
are concerned, recent investigations have produced interesting 
data (see Table 2). An early   hypothesis suggested that variability 
Table 1 Conditions affecting hemoglobin F levels
Hereditary diseases
  •   Thalassemia syndromes (homozygous beta thalassemia,  
heterozygous beta thalassemia, delta beta thalassemia,  
homozygous and heterozygous)
  •   Other hemoglobinopathies (hereditary persistence of hemoglobin F,  
homozygous and heterozygous, sickle cell anemia, hemoglobin C,  
hemoglobin E, Hemoglobin Lepore syndrome, some  
unstable hemoglobin)
  • Hereditary spherocytosis
  •   Hemoglobin variants with retention time similar to that  
of hemoglobin F
Acquired conditions
Non neoplastic blood disorders
  • Pernicious anemia
  • Sideroblastic anemia
  • Pure red cell aplasia
  • Refractory normoblastic anemia
  • Aplastic anemia
  • Paroxysmal nocturnal hemoglobinuria
  • Recovery from bone marrow transplant
Neoplastic blood disorders
  • Acute leukemias
  • Erythroleukemia
  • Juvenile chronic myeloid leukemia
  • Marrow neoplastic metastases
  • Hepatoma
Treatment-related situations
  • Antileukemic chemotherapy
  •   Therapy with hydroxyurea, aza-deoxycytidine,  
butyrates, and erythropoietin
Miscellaneous
  • Pregnancy
  • Hyperthyroidism
  • Chronic renal disease
  • Trisomy 13 (Palau syndrome)Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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in HbF was mainly due to   independent genetic factors, an effect 
particularly evident in patients with SCD.10 A seminal study 
showed that a variation of genetic determinants on chromosome 
11p16 was involved in the expression of HbF, and precisely at 
position 158.11 However, the effect of such variation is modest 
in normal people, and its presence is not always associated 
with high HbF, but variants at this locus have a considerable 
frequency in certain populations like Asian Indians, in whom it 
was first studied and found to be associated with the presence 
of moderate levels of HbF in normal individuals.12
A second determinant was found in a large Indian   family 
with beta thalassemia and hereditary persistence of fetal 
hemoglobin, situated in a region on chromosome 6q23-q24, 
between the HBS1L and MYB genes.13 This locus was there-
fore termed HMIP (HBS1L-MYB intergenic polymorphism), 
and is an important component (about 19%) of the F cell trait 
in the general population.
A strong association with HbF level was eventually 
observed with a third locus, situated on chromosome 2p15, 
namely the BCL11A, leading to the   hypothesis that a prod-
uct of this locus, a multizinc finger   transcription factor, may 
encode a stage-specific regulator of HbF   expression.14 On the 
clinical side, extensive research   carried out among patients in 
Sardinia and other groups showed that a variant of BCL11A 
was strongly   associated with   individuals having high HbF 
levels, as well as with patients having mild forms of thalas-
semia and SCD.15 A very recent study, based on genome-wide 
association, has also identified a regulatory region in the 
olfactory receptor gene cluster (on chromosome 11), which 
may play a role in gamma-globin gene expression.16
Finally, it should be stressed that, although recent   progress 
in the genetics of HbF has not yet promoted   therapeutic 
  applications, every contribution to the   understanding of 
genetic mechanisms presiding over HbF synthesis and to the 
HbF-to-HbA switch is a necessary premise for the formulation 
of treatment strategies for severe hemoglobin disorders.
Inducers of fetal hemoglobin
Agents capable of inducing production of fetal hemoglobin 
have been known for many years, and have also been used 
in clinical trials (Table 3). 
1)  It was in the early 1980s that 5-azacytidine was shown 
to be able to reinduce production of HbF in adults, as well as 
in experimental animals. A few patients with beta thalassemia 
and SCD treated with this drug showed a modest correction 
of globin chain imbalance and had lower transfusion needs.17 
However, the possibility that such treatment could have an 
oncogenic effect discouraged the undertaking of these tri-
als. It was only years later that a derivative of azacytidine, 
namely deoxy-azacytidine, or decitabine, was found to be 
effective in reactivating   production of fetal hemoglobin, 
and was therefore started in regular trials on SCD patients.18 
As for possible toxic effects from this drug, only revers-
ible neutropenia was observed, while tests on experimental 
animals not only showed absence of tumorigenic action, 
but even suggested a decrease of tumor formation in mice 
predisposed to cancer.19
Parenteral administration of decitabine can produce a 
notable increase of HbF levels as well as stimulate erythroid 
differentiation in SCD patients.20 Oral preparations have also 
been tested in animals, with the aim of making them more 
acceptable to patients.21 More investigations are needed to 
study possible long-term adverse effects of this compound.
Great interest was devoted to the study of the mecha-
nism of action of different compounds in the induction 
of HbF. Early suggestions of a relevant effect on DNA 
  hypomethylation at the promoters of the gamma-globin gene3 
were   followed by the realization that different mechanisms 
may be involved. A unifying theory has been proposed, based 
on the   assumption that a variety of cellular stresses and 
stimuli can   promote coordinated stress responses, including 
  gamma-globin gene activation. Different signaling pathways, 
like cAMP, p38MAPK, and others may be involved.22
2)  Hydroxyurea (hydroxycarbamide [HC]) has been 
known for a long time as a well tolerated oral treatment for 
some myeloproliferative disorders. Its action on HbF produc-
tion, first observed in baboons, was then tested and demon-
strated in clinical trials on SCD patients. Predictably, bone 
marrow suppression was observed after long-term treatment, 
but this effect was reversible.3 The mechanism of action of 
this compound seems to be mediated through the induction 
of a GTP-binding protein SAR, which modulates expres-
Table 2 Genetic determinants of hemoglobin F production
Locus Chromosome
 •  Xmn1-HBG2 11
 •  HMiP (HBS1L-MYB intergenic polymorphism) 6
 •  BCL11A 2
 •  OR5 -OR6 (olfactory receptor gene cluster)  11
Table 3 inducers of hemoglobin F production
 •  Nucleoside analogs, ie, azacytidine and decitabine
 •  Hydroxyurea (hydroxycarbamide)
 •    Histone deacetylase inhibitors, ie, butyrate, trychostatin A, apicidin, 
scriptaid, hydroxyamides
 •    Others, including erythropoietin, valproate, thalidomide derivatives,  
kit ligandJournal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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sion of the gamma-globin gene in erythroid cells.23 Very 
good results have been reported recently in a 17-year trial 
  carried out in a variety of sickle cell syndromes. A dramatic 
  reduction of severe pain crises, transfusion requirements and 
hospital admissions was obtained, showing how prolonged 
and tolerable treatment with hydroxyurea can profoundly 
modify the natural history of the disease.24
As for the mechanism of action of hydroxyurea, a series of 
investigations point to an effect on genes which are involved in 
hemoglobin synthesis. One of these genes is the transcription 
factor, EGR1, which is one of the most   upregulated genes 
following HC treatment. Another group of genes, represented 
by CENTB1 (centaurin, beta 1), ARHGAP4 (Rho GTPase 
activating protein 4), and RIN3 (Ras and Rab interactor 3), 
were found to be induced after hydroxyurea administration.25 
Another study, carried out in reticulocytes from SCD patients 
after hydroxyurea treatment showed an altered expression of 
genes associated with the regulation of globin   expression, 
like SUD53, FZD5, and PHC3.26 These results show that 
hydroxyurea produces significant changes in the gene 
  expression pattern, with activation of   transcription   factors and 
pathways involved in signal transduction,   eventually leading 
to an increase of globin gene expression.
The search continues to find agents able to enhance the 
action of hydroxyurea in SCD patients. In this context, a 
compound which has been known for a long time as an HbF 
inducer is erythropoietin, which is capable of increasing 
the amount of F cells and HbF concentration. A synergistic 
action was seen when erythropoietin was associated with 
hydroxyurea, either simultaneously or sequentially, and 
of special interest is the finding of a good erythropoietin 
response in patients who were hydroxyurea-intolerant. 
In this case, erythropoietin treatment made it possible to 
tolerate hydroxyurea dosage escalation, with an increase 
in F cells and only minor side effects.27 More studies are 
in progress to investigate the potential of such a drug 
combination.
3)  Butyrate was the earliest of a number of compounds 
used in this context because of their action as inhibitors of 
  histone deacetylase. It is indeed known that by promoting his-
tone acetylation, butyrate increases the transcription rate of the 
  gamma-globin gene, as well as the translation of gamma-globin 
mRNA.28 It has also been demonstrated that transcription 
  factors like GATA1 and NF-E32 are involved.29
Other histone deacetylase inhibitors, and butyrate itself, 
have also shown a different mechanism of action, namely 
through activation of the p38MAP kinase pathway. The   effector 
molecules have been identified by   Sangerman et al as CREB1 
and ATF2, acting via the   aforementioned pathway, which 
therefore appears to be one of the main mediators of gamma-
globin gene regulation.30 Many more compounds, acting 
as histone deacetylase inhibitors, have been mentioned as 
beneficial agents in sickle cell disease.31
New classes of synthetic histone deacetylase inhibitors, 
defined as aroyl-pyrrolyl hydroxyamides and uracil-based 
hydroxyamides, have also been tested. Of 24 agents, two 
were found to be active for their ability to induce HbF 
in   different models of erythroid differentiation. The two 
  compounds increased the γ/(γ + β) ratio in normal erythroid 
cells.   Interestingly, both compounds were also effective in 
  correcting the impaired in vitro maturation of beta   thalassemic 
erythroblasts.32 These results and those obtained with other 
types of histone deacetylase inhibitors seem to suggest that 
compounds acting as epigenetic modifiers, namely capable 
of modulating gene expression, may be a promising area of 
investigation.
4) A number of disparate compounds has been suggested 
as endowed with stimulating activity on the production of 
gamma-globin and HbF. One of them is valproate, which 
was found to induce hemoglobin synthesis in erythroid cells, 
again by activation of the p38 pathway.33
An interesting compound tried in this context is the kit 
ligand, an important cytokine for the initiation of hemopoiesis. 
In unilineage erythroid cultures of 20 patients with major beta 
thalassemia or thalassemia intermedia,   addition of kit ligand 
induced a marked increase of   gamma-globin synthesis, 
thus reaching HbF levels three-fold higher than in control 
cultures.34
Worth mentioning is the effect of thalidomide, which 
seems capable of inducing HbF expression via activation 
of the same p38MAPK signaling pathway, as well as the 
action of two thalidomide analogs, used as immunomodu-
lators, which have been shown to possess, among other well 
known activities, a stimulating effect on HbF   production. 
Such   compounds, ie, pomalidomide and lenalinamide, 
recently tested on early erythroid progenitors in vitro, caused 
increased proliferation of immature erythroid cells, regulated 
hemoglobin transcription, and induction of HbF without 
cytotoxicity. A synergistic effect was also observed in 
association with hydroxyurea.35
Cell transplant and cell engineering
An effective strategy employed in SCD is the transplantation 
of hemopoietic bone marrow or cord blood, thus delegating 
to transplanted stem cells the task of providing normal levels 
of hemoglobin A. However, it has been calculated that, up Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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to 2008, more than 1600 allogeneic transplants had been 
performed in beta thalassemia, but many fewer were done 
in SCD, perhaps because fewer patients in the advanced 
stages were eligible, due to the presence of severe vascular 
damage.36
This option is moreover restricted by limited availability 
of suitable donors and the severe effects of marrow ablation 
treatment, including reduced fertility, especially in women. 
To overcome such limitations, unrelated donors have been 
used with some success and nonablative regimens have also 
been employed, while, in order to preserve reproductive 
potential in women, ovarian tissue preservation and subse-
quent implantation have been employed, obtaining successful 
embryo development.37
More recently, sophisticated strategies, based on cell 
engineering, have been developed to transfer correcting 
genes in patients with a single gene defect. It is certainly 
fair to mention some remarkable success obtained by gene 
therapy in genetic immunodeficiency diseases.38 As far as 
SCD is concerned, a search has been going on for a long time 
to find an effective gene vector which would allow transfer 
of a desired gene into hemopoietic stem cells. After early 
attempts using gamma retroviral vectors to transduce globin 
genes into dividing stem cells,39 lentiviral vectors, a subclass 
of retroviruses capable of transducing not only proliferating 
but also quiescent cells, proved more effective.40 It has been 
stressed that lentiviral vectors should be erythroid-specific, 
differentiation- and stage-restricted, position-independent, 
and sustainable over time.41
This approach can be adopted for SCD, forcing the 
expression of fetal hemoglobin, which, even at low con-
centration, has been shown to exert a potent   antisickling 
effect.42 On the other side, it has been noted that gene therapy 
for SCD, to be effective, should induce a therapeutic gene 
in the greatest part of the red cell population, because even 
a small proportion of remaining sickle cells may cause 
  vaso-occlusion and severe ischemia.43
As for the cell type to be used for such correction, the 
most primitive progenitors, namely embryonic stem cells, 
were used initially in mice with SCD by the   technique of 
gene targeting and homologous recombination.44 The clinical 
limitation of this procedure is at present the restriction 
on human embryonic stem cell research.   However, great 
  attention has been devoted recently to a special class 
of hemopoietic stem cells, which can be used for cell 
  engineering, namely induced pluripotent stem cells, which 
can be obtained by reprogramming somatic cells and 
restoring the potential to develop new differentiated cells.45 
However, many   questions are still unsolved about   possible 
applications of human induced pluripotent stem cells in cell 
engineering and   regenerative medicine, like the   permanence 
of foreign DNA in the host genome. New techniques have 
therefore been developed to remove the integrated DNA 
from the genome of induced pluripotent stem cells,46 making 
them safer for clinical use.
It is apparent that a number of modalities are 
now available to try to modify the genetic defects in 
  hemoglobinopathies, including the sickle mutation. This 
brings to the forefront the issue of safety requirements in 
gene therapy. It is indeed well known that, in a few cases of 
genetic   immunodeficiency, a neoplastic proliferation was 
triggered by insertional   mutagenesis of a proto-oncogene, 
raising the possibility that recombinant retroviral vectors 
could influence the expression of nearby genes.47 Although 
gamma-globin gene   vectors seem less prone to induce the 
expression of dangerous genes, this is a problem which 
requires great attention and is   presently the object of 
intensive research.
Progress in methods for fetal 
hemoglobin determination
Unfortunately, there is no international standardization 
program for HbF, and no quality specifications have been 
reported so far, although these are available for glycated 
hemoglobin and total hemoglobin. Therefore, it is   important 
to outline criteria used for measurement units and the 
  reference interval for the expression of HbF. A uniform 
measurement unit, used worldwide, is the relative   percentage 
of total hemoglobin, although this is not in line with the 
  international SI system. Every professional laboratory should 
build its own reference interval, by measuring HbF in at 
least 100 adults, who are not iron-depleted and not carriers 
of alpha or beta thalassemia.
It is generally assumed that HbF above 1% in a healthy 
adult individual could be due either to a genetic defect or to 
some acquired condition. A review on this topic has been 
proposed recently as a guide for the interpretation of clinical 
HbF data and a valuable aid to correct diagnosis.48
Among the more sophisticated methods for the 
  assessment of HbF levels, we may include the determination 
of single nucleotide polymorphisms, whose variations have 
received wide application in molecular genetics.49 It is to 
be expected that studies of genomic regions   associated 
with HbF levels will provide interesting indications for 
the diagnosis and perhaps the therapeutic approach to 
hemoglobinopathies.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Future directions
•  Identification of the full set of genes controlling gamma-
globin synthesis and HbF production
•  Optimization of the efficacy of compounds already used 
for activating HbF production and exploration of new 
drug combinations
•  Reduction of the risk-benefit ratio of stem cell transplants, 
making it possible to treat a larger number of patients
•  Attempt to translate gene therapy from the experimental 
arena to clinical reality, keeping into account its dangers 
and limitations.
The first point implies further efforts along a pathway 
which has already produced promising results. It has been 
stressed, however, that only about half of the genetic factors 
influencing HbF control has been identified and that multiple 
loci, perhaps of limited relevance, still have to be located.5 
Environmental factors also await to be clarified and in this 
context more comparisons between affected populations in 
different parts of the world and groups exposed to different 
life situations should be profitable.50
As for the second point, the list of compounds which 
have been proposed as therapeutic agents is quite   impressive, 
but so far hydroxyurea is the only one subjected to exten-
sive clinical trials and shown to produce satisfactory 
results, although not in all cases. More research is needed 
to   elucidate the mechanism of action of hydroxyurea and 
the other compounds, because a better pharmacological 
treatment will reduce the need for the most difficult and 
expensive forms of therapy. More combination treatments 
will undoubtedly be tried (keeping hydroxyurea as the main 
component) with the aim to formulate the best scheme for 
any individual patient, according to age, gender, and severity 
of disease. Further investigations will also be centered on 
practical aspects of drug presentation, eg, the possibility to 
give decitabine in an oral form,21 which has been already 
tried in monkeys and is likely to prove more acceptable in 
human patients.
Stem cell transplantation is commonly considered the only 
curative treatment for SCD and, as such, is receiving special 
attention. A number of reports have highlighted the problems 
involved using reduced intensity preparative regimens for 
treating these patients and many failures have been reported, 
due in most cases to lack of sustained donor engraftment.51 
However, in a recent study of   nonmyeloablative allogeneic 
hematopoietic stem cell transplantation, including total body 
irradiation and treatment with immune suppressors, a stable, 
mixed donor recipient chimerism was achieved, with reversal 
of the sickle cell phenotype.52
Furthermore, in addition to “technical” problems, there 
is a daunting issue of ethical impact pending on hemopoietic 
stem cell transplantation, namely the opportunity of giving 
birth to a sibling in order to provide a suitable donor for a 
severely affected child. The morality of this practice has been 
indeed questioned, particularly if programming a donor is 
performed exclusively as a utilitarian operation.53
The problems involved in gene therapy designs are still 
a great challenge and more research is certainly needed. 
As for human trials, worries have been raised very recently, 
because it was shown that a patient with beta thalassemia, 
treated successfully with a lentivirus-modified beta-globin 
gene in 2007, and presently transfusion-free, now produces 
about 10% of blood cells with an insertion which may give 
a growth advantage and thus tumorigenic potential.54
One area of investigation is therefore the search for 
new types of vectors, possibly nonviral. In this respect, it is 
worthwhile to mention very recent progress obtained using 
biodegradable polymeric vectors, and a class of these vectors 
has recently been developed and optimized for high trans-
fection efficiency.55 This may encourage more investigation 
along this line.
Further developments are awaited following the   previously 
quoted attempts to correct the SCD mutation by homologous 
recombination. Actually, this procedure,   proposed earlier in a 
mouse model,56 was performed recently in a patient with beta 
thalassemia, with skin fibroblasts removed,   transformed into 
pluripotent stem cells, and then differentiated into hemopoietic 
stem cells, capable of   producing normal adult hemoglobin. 
It was even suggested to collect cells from amniotic fluid 
or chorionic villus sampling, used for prenatal diagnosis, 
reprogram them into induced pluripotent stem cells, correct 
the mutation, and reinfuse them during the perinatal period, 
ie, an option for very early treatment before organ damage 
takes place.57
As for the tools necessary to introduce specific changes 
into the genome of patient-derived induced pluripotent stem 
cells, a recent approach is based on zinc finger nuclease 
technology, which enables targeting of a specific DNA 
binding domain to a preselected chromosomal site.58,59 Both 
approaches allowed the introduction of defined genetic 
modifications in highly sensitive induced pluripotent stem 
cells, without reported side effects on the pluripotency of 
these cells or their genetic stability.
Mention was made before of an encouraging improve-
ment obtained with severe thalassemia by gene therapy.54 
However, as far as SCD is concerned, 100 years have 
passed since the first description of the disease and, despite Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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remarkable progress in the knowledge of pathogenetic and 
clinical aspects, a consistently effective treatment remains 
elusive and requires further investigations.60
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